Chairman and Managing Director – Qing LIU PhD
After achieving a BSc in Chemical engineering from Tsinghua University and an MSc in Polymer Science from Sichuan University, Qing gained a PhD from Twente University, Netherlands for his work in biomaterials. After that, Qing continued his research in tissue engineering and biomaterials as a research fellow in Rice University, USA and Temple University, USA. Later, Qing joined Celgene, a global biopharmaceutical company, and became the R&D director, gaining rich experience in R&D, management, medical device GMP and FDA approval applications. In 2007, Qing founded 3D Biotek. In the same year, 3D Biotek was approved to move into the Commercialization Center for Innovation Technologies which was funded by New Jersey government. In 2009, 3D Biotek received an award of “2009 Incubator Company to Watch” in the Award Gala held by the New Jersey Technology Council (NJTC). This company was also awarded an SBIR Phase 1 grant from NIH and an Edison Innovation R&D grant from NJ Commission on Science and Technology for its work on 3D biodegradable porous polymer scaffolds.
Qing is a standing committee member of China Association for Medical Device Industry Vascular Devices Branch, member of the China Endovascology Committee and many other related organizations.
Qing has 24 patents, and has published 28 scientific papers and 3 academic books. He has been a review committee member of NIAMS, SBIR, and the 13th five-year special funds for additive manufacturing. In 2012, Qing became a review committee member of the Review Meeting of Beijing Haidian International R&D Cooperation, and won a second class prize of the State Scientific and Technological Progress Award. Qing received a “Haiying” title in 2014, “Haiju”, “Gaoju” titles in 2015.
Qing is currently a part-time professor in the Institute of Advanced Materials and Nanobiomedical Research, Tongji University.
Chief Scientist – Qinghong ZHAO PhD
After achieving a BSc from Sichuan University, Qinghong obtained his MSc and PhD from Case Western Reserve University, USA. He has 2 patents, and has published 28 scientific papers. Before joining AMT, Qinghong was working on the bioabsorbable peripheral stent in Abbott, USA. Qinghong has been a researcher on implantable medical devices in a number of international companies such as Medtronic. He has rich experience in the research of a series of medical products including vascular prosthesis, soft tissue and bone repair materials, ventricular assist device, and biodegradable materials. Many of these products have been commercialized.
Chief Medical Officer, CMO – Alexander NIKANOROV MD
Alexander worked in Abbott, USA from 2003 to 2013 as a clinical research director and participated in the development of bioresorbable vascular scaffolds and many other related products. During his stay in Abbott, Alexander gained rich experience in the clinical research of implantable medical products and became a TCT/cardiovascular research foundation (CRF) fellow in 2010. From 2013, Alexander joined the international division of St Jude Medical and became the director of clinical cardiovascular. Alexander has close cooperative relationships with many organizations and institutes such as Cardiovascular Research Foundation (CRF), Stanford University, Massachusetts Institute of Technology (MIT), etc. He is also one of the organizers of TCT-Russia conference.